Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats

被引:20
作者
Zhang, Min
Ballard, Michael E.
Kohlhaas, Kathy L.
Browman, Kaitlin E.
Jongen-Rêlo, Ana-Lucia
Unger, Liliane V.
Fox, Gerard B.
Gross, Gerhard
Decker, Michael W.
Drescher, Karla U.
Rueter, Lynne E.
机构
[1] Abbott Labs, Neurosci Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
[2] Abbott GmbH & Co KG, CNS Pharmacol, Ludwigshafen, Germany
关键词
prepulse inhibition; D-2; receptor; D-3; schizophrenia; antipsychotics; neurodevelopmental model;
D O I
10.1038/sj.npp.1300985
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Schizophrenic patients typically exhibit impairment of sensorimotor gating, which can be modeled in animal models such as the test of prepulse inhibition of startle response (PPI) in rodents. It has been found that antipsychotics enhanced PPI in DBA mice and reversed the PPI deficit induced by neonatal ventral hippocampal (NVH) lesions in rats. However, the relative involvement of D-3 and D-2 receptors in these effects is unknown since all antipsychotics are D-2/D-3 antagonists with limited binding preference at D-2 receptors. Therefore, in the current study, we investigated the influence of several dopamine antagonists with higher selectivity at D-3 vs D-2 receptors on PPI in DBA/2J mice and in NVH-lesioned rats. The PPI in DBA/2J mice was enhanced by the nonselective D-2/D-3 antagonists, haloperidol at 0.3-3 mg/kg, or risperidone at 0.3-1 mg/kg, while PPI-enhancing effects were observed after the administration of higher doses of the preferential D-3/D-2 antagonist, BP 897 at 8 mg/kg, and the selective D-3 antagonists, SB 277011 at 30 mg/kg and A-437203 at 30 mg/kg. No effect was observed following the treatment with the selective D-3 antagonist, AVE 5997 up to 30 mg/kg. The PPI deficits induced by NVH lesions were reversed by haloperidol but not by the more selective D-3 antagonists, A-437203 and AVE 5997. BP 897 enhanced PPI nonselectivity, that is, in both lesioned and nonlesioned rats. In summary, the present study indicates that PPI-enhancing effects induced by antipsychotics in DBA/2J mice and in NVH-lesioned rats are unlikely to be mediated by D-3 receptors.
引用
收藏
页码:1382 / 1392
页数:11
相关论文
共 78 条
  • [21] STARTLE RESPONSE MODELS OF SENSORIMOTOR GATING AND HABITUATION DEFICITS IN SCHIZOPHRENIA
    GEYER, MA
    SWERDLOW, NR
    MANSBACH, RS
    BRAFF, DL
    [J]. BRAIN RESEARCH BULLETIN, 1990, 25 (03) : 485 - 498
  • [22] Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
    Geyer, MA
    Krebs-Thomson, K
    Braff, DL
    Swerdlow, NR
    [J]. PSYCHOPHARMACOLOGY, 2001, 156 (2-3) : 117 - 154
  • [23] Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
    Giros, B
    Jaber, M
    Jones, SR
    Wightman, RM
    Caron, MG
    [J]. NATURE, 1996, 379 (6566) : 606 - 612
  • [24] GIROS B, 1990, CR HEBD ACAD SCI, V3, P501
  • [25] Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia
    Glenthoj, BY
    Hemmingsen, R
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1997, 21 (01) : 23 - 46
  • [26] The structure of lead stabilizers. I: Basic lead carboxylates
    Grossman, RF
    Krausnick, D
    [J]. JOURNAL OF VINYL & ADDITIVE TECHNOLOGY, 1997, 3 (01): : 7 - 11
  • [27] BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization
    Guillin, O
    Diaz, J
    Carroll, P
    Griffon, N
    Schwartz, JC
    Sokoloff, P
    [J]. NATURE, 2001, 411 (6833) : 86 - 89
  • [28] Gurevich EV, 1997, ARCH GEN PSYCHIAT, V54, P225
  • [29] Distribution of dopamine D3 receptor expressing neurons in the human forebrain:: Comparison with D2 receptor expressing neurons
    Gurevich, EV
    Joyce, JN
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) : 60 - 80
  • [30] Pathways to schizophrenia: the impact of environmental factors
    Howes, OD
    McDonald, C
    Cannon, M
    Arseneault, L
    Boydell, J
    Murray, RM
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S7 - S13